Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Alain, Luxembourg"'
Autor:
Susanne K. Kjaer, Thea E. Hetland Falkenthal, Karin Sundström, Christian Munk, Tina Sture, Oliver Bautista, Sonali Rawat, Alain Luxembourg
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
A pivotal study in women aged 16–26 years demonstrated that the nine-valent human papillomavirus (9vHPV) vaccine was efficacious against high-grade cervical dysplasia related to the HPV types covered by the vaccine. To evaluate whether effectivenes
Externí odkaz:
https://doaj.org/article/a3ca8da01b49464694a4a34ab2a7fce8
Autor:
Katrina M. Nolan, Brent Seaton, Joseph Antonello, Yuhua Zhang, Lauren Cook, Krystyn Delfino, Leonard J. Rubinstein, Kyeongmi Cheon, Thomas Group, Alain Luxembourg, Sheri Dubey
Publikováno v:
mSphere, Vol 8, Iss 2 (2023)
ABSTRACT Two multiplex immunoassays are routinely used to assess antibody responses in clinical trials of the 9-valent human papillomavirus (9vHPV) vaccine. The HPV6/11/16/18/31/33/45/52/58 competitive Luminex immunoassay (HPV-9 cLIA) and HPV6/11/16/
Externí odkaz:
https://doaj.org/article/fc915b5b917b4300a7a5ca8400155d0e
Autor:
Ivette Maldonado, Manuel Plata, Mauricio Gonzalez, Alfonso Correa, Claudia Nossa, Anna R. Giuliano, Elmar A. Joura, Alex Ferenczy, Brigitte M. Ronnett, Mark H. Stoler, Hao Jin Zhou, Amita Joshi, Rituparna Das, Oliver Bautista, Thomas Group, Alain Luxembourg, Alfred Saah, Ulrike Kirsten Buchwald
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
Among women aged 27–45 years, the quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the placebo-controlled FUTURE III study (NCT00090220; n = 3253). The qHPV vaccine was al
Externí odkaz:
https://doaj.org/article/c896750b7beb407cac4a4f28dd301218
Autor:
Suzanne M. Garland, Manjula Anagani, Neerja Bhatla, Sukanta Chatterjee, Sanjay Lalwani, Cecil Ross, Thomas Group, Jianxin Lin, Alain Luxembourg, Anuj Walia, Yingmei Tu
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) and 9-valent HPV (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccines have demonstrated efficacy, immunogenicity, and safety in international clinical trials. We report outcomes from three complet
Externí odkaz:
https://doaj.org/article/cf2d2916be8d4ca599a28268dd9021ac
Autor:
Vu Dinh Thiem, Nguyen Dang Quang, Nguyen Hai Tuan, Kyeongmi Cheon, Nancy Gallagher, Alain Luxembourg, Thomas Group, Cyrus Badshah
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 1980-1985 (2021)
This open-label, single-center, Phase 3 study (NCT03546842) assessed the immunogenicity and safety of the nine-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccine in Vietnamese males and females, with the aim to support 9vHPV va
Externí odkaz:
https://doaj.org/article/21f29e53122346d1a140f3d78bb5fe18
Autor:
Susanne K. Kjaer, Mari Nygård, Karin Sundström, Christian Munk, Sophie Berger, Mensur Dzabic, Katrin Elisabeth Fridrich, Marianne Waldstrøm, Sveinung Wergeland Sørbye, Oliver Bautista, Thomas Group, Alain Luxembourg
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 4, Pp 943-949 (2021)
A long-term follow-up (LTFU) of the nine-valent human papillomavirus (9vHPV) vaccine efficacy study in young women aged 16–26 years was initiated to evaluate if vaccine effectiveness for up to 14 years post-vaccination will remain above 90%. Vaccin
Externí odkaz:
https://doaj.org/article/ee37a6c3f7494a4e8de61375851cbf26
Autor:
Darron R. Brown, Xavier Castellsagué, Daron Ferris, Suzanne M. Garland, Warner Huh, Marc Steben, Cosette M. Wheeler, Alfred Saah, Alain Luxembourg, Se Li, Christine Velicer
Publikováno v:
Tumour Virus Research, Vol 13, Iss , Pp 200236- (2022)
Background: Estimates of the humoral immune response to incident human papillomavirus (HPV) infections are limited. Methods: In this post hoc analysis of 3875 women aged 16–23 years from a 4-valent HPV vaccine trial (NCT00092482), HPV seroprevalenc
Externí odkaz:
https://doaj.org/article/d9cb3b27b14041a69c57be94196cbbe2
Autor:
Ana Maria Guevara, Eugenio Suarez, Alejandro Victoria, Hextan YS Ngan, Angelica Lindén Hirschberg, Edison Fedrizzi, Oliver Bautista, Christine Shields, Amita Joshi, Alain Luxembourg
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 1, Pp 141-145 (2019)
Background: This exploratory analysis was conducted to characterize the level of HPV types 6/11 antibodies in peripartum maternal blood and in cord blood of infants born to women who received 9-valent HPV (9vHPV) vaccine or quadrivalent HPV (qHPV) va
Externí odkaz:
https://doaj.org/article/3d6f4d6ed04b412cb70116f750d6a281
Autor:
Sven-Eric Olsson, Jaime Alberto Restrepo, Julio Cesar Reina, Punnee Pitisuttithum, Angels Ulied, Meera Varman, Pierre Van Damme, Edson Duarte Moreira, Jr., Daron Ferris, Stanley Block, Oliver Bautista, Nancy Gallagher, Jennifer McCauley, Alain Luxembourg
Publikováno v:
Papillomavirus Research, Vol 10, Iss , Pp 100203- (2020)
Background: The nine-valent human papillomavirus (9vHPV) vaccine protects against infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal 36-month Phase III immunogenicity study of 9vHPV vaccine in 9- to 15-year-
Externí odkaz:
https://doaj.org/article/bc2a7b4c77394d1eaac73e65d41602c2
Autor:
Daron G. Ferris, Darron R. Brown, Anna R. Giuliano, Evan Myers, Elmar A. Joura, Suzanne M. Garland, Susanne K. Kjaer, Gonzalo Perez, Alfred Saah, Alain Luxembourg, Christine Velicer
Publikováno v:
Papillomavirus Research, Vol 10, Iss , Pp 100202- (2020)
Objectives: The natural history of human papillomavirus (HPV) infection has been studied extensively in young women; this study investigated HPV infection in adult women. Methods: Data from 3817 women aged 24–45 years in a global trial of the 4-val
Externí odkaz:
https://doaj.org/article/d38ae64d011440be83433bef2fcbfdf3